Baricitinib Provides Holistic Improvement in Scalp, Eyebrow and Eyelash Regrowth in Adolescents With Severe Alopecia Areata

Main Article Content

Bianca Maria Piraccini
Private Dermatology Practice, Bologna, Italy

Manabu Ohyama
Kyorin University School of Medicine, Tokyo, Japan

Lisa Arkin
University of Wisconsin School of Medicine and Public Health, Madison, USA

Arash Mostaghimi
Brigham and Women's Hospital, Boston, USA

Angelina Sontag
Eli Lilly and Company, Indianapolis, USA

Kriti Singh
Eli Lilly and Company, Indianapolis, USA

Tuhina Das
Eli Lilly and Company, Indianapolis, USA

Jennifer Soung
Southern California Dermatology, Santa Ana, USA

Keywords

Alopecia Areata

References

1. King B, et al. N Engl J Med. 2022;386:1687-1699.

2. King B, et al. Lancet. 2023;401:1518-1529.

3. Liu LY, et al. J Am Acad Dermatol. 2016;75:806-812.

4. Liu LY, et al. J Am Acad Dermatol. 2018;79:556-558.

5. Aldhouse NVJ, et al. J Patient Rep Outcomes. 2020;4:76.

6. Wyrwich KW, et al. Am J Clin Dermatol. 2020;21:725-732.

7. Amador GJ, et al. J R Soc Interface. 2015;12:20141294.

8. Sadr J, et al. Perception. 2003;32:285-293.

9. King B, et al. J Am Acad Dermatol. 2022;86:359-364.

10. Liu LY, et al. J Investig Dermatol Symp Proc. 2020;20:S37-S40.

11. OLUMIANT (baricitinib) [Prescribing Information] Indianapolis, IN: Eli Lilly and Company, 2022.

12. Senna M, et al. J Eur Acad Dermatol Venereol. 2024;38:583-593.

Article Sidebar

PDF
Published
2025-11-10
DOI: https://doi.org/10.25251/pnxf4156

Article Details

How to Cite
1.
Baricitinib Provides Holistic Improvement in Scalp, Eyebrow and Eyelash Regrowth in Adolescents With Severe Alopecia Areata. J of Skin. 2025;9(6):s667. doi:10.25251/pnxf4156
Issue
Vol. 9 No. 6 (2025): November 2025 Issue
Section
Alopecia
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 > >>